While the test was conducted in NSCLC, the FDA approval includes existing solid tumor indications for Keytruda. Merck is ...
In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, ...
If you have been watching Merck (MRK) lately, the recent FDA approval for Keytruda QLEX has probably caught your eye. This ...
The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and ...
The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.
For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent ...
Merck & Co., Inc. (NYSE:MRK) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In. Following a decline in revenue ...
Everyday Health on MSN
Blockbuster Cancer Drug Keytruda Now Available as a Time-Saving Shot
Patients taking the immunotherapy drug Keytruda (pembrolizumab) may now have the option to take it as a quick shot instead of ...
Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...
The FDA has approved a new injectable version of cancer drug Keytruda as Merck seeks to protect its market dominance. Here are five things to know: ...
FDA approves Keytruda Qlex, a subcutaneous injection version of the widely used cancer therapy Keytruda Patients can now ...
Though MSD's subcutaneous Keytruda is more patient-centric, analysts are sceptical of the drug’s capacity to stave off ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback